Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248372 | 0.81 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2MAPK1KDM4EHPGD | |
| SCHEMBL17818836 | 0.78 | SMN1; SMN2 (0.36) | ALDH1A1SMN1; SMN2MAPK1KDM4EHPGD | |
| SCHEMBL9278400 | 0.77 | CTSD (0.41) | ALDH1A1SMN1; SMN2KDM4ECTSDMAPT | |
| SCHEMBL11082976 | 0.75 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2MAPK1KDM4EHPGD | |
| SCHEMBL4097495 | 0.73 | TSHR (0.39) | ALDH1A1SMN1; SMN2MAPK1KDM4EHPGD | |
| SCHEMBL14176733 | 0.72 | GAA (0.41) | ALDH1A1SMN1; SMN2MAPK1KDM4EHPGD | |
| SCHEMBL22223973 | 0.70 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2MAPK1KDM4EHPGD | |
| SCHEMBL11538765 | 0.68 | SMN1; SMN2 (0.31) | SMN1; SMN2KDM4E | |
| SCHEMBL11939846 | 0.68 | GAA (0.41) | ALDH1A1SMN1; SMN2MAPK1KDM4EHPGD | |
| SCHEMBL528211 | 0.68 | MAPK1 (0.65) | ALDH1A1SMN1; SMN2MAPK1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| EP-4422750-A1 | LRRK2 INHIBITORS | H. Lundbeck A/S (DK) | 2024-09-04 | — | — | EP | disclosed |
| CN-118251397-A | LRRK2 inhibitors | H.隆德贝克有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11993612-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2024-05-28 | — | — | US | disclosed |
| US-20230416272-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-12-28 | — | — | US | disclosed |
| US-11780851-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-11780851-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-11780851-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| WO-2023073013-A9 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-08-17 | — | — | WO | disclosed |
| US-20230144725-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-05-11 | — | — | US | disclosed |
| US-20230144725-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-05-11 | — | — | US | disclosed |
| WO-2023073013-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-05-04 | — | — | WO | disclosed |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| EP-3652179-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-05-20 | — | — | EP | disclosed |
| CN-110891954-A | Inhibitors of leucine-rich repeat kinase 2 | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-03-17 | — | — | CN | disclosed |
| WO-2019012093-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019012093-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-17 | — | — | WO | disclosed |
| US-4705786-A | Novel oxadiazolyl-1,4-dihydropyridines useful as antihypertensive agents | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-11-10 | — | — | US | disclosed |
| EP-0177965-A2 | Novel oxa- and thiadiazolyl derivatives and their use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993612-B2 | LRRK2 inhibitors | LRRK2, PARK7, PINK1 | ALDH1A1 2464/4885SMN1; SMN2 351/4885MAPK1 148/4885 |
| US-11780851-B2 | LRRK2 inhibitors | LRRK2, PARK7, PINK1 | ALDH1A1 2464/4885SMN1; SMN2 351/4885MAPK1 148/4885 |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | LRRK2, PARK7, PINK1 | ALDH1A1 4577/4885SMN1; SMN2 66/4885MAPK1 232/4885 |
| US-20230416272-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | ALDH1A1 2464/4885SMN1; SMN2 351/4885MAPK1 148/4885 |
| US-20230144725-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | ALDH1A1 2464/4885SMN1; SMN2 351/4885MAPK1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.